Clinical Trials in Gorna Oryahovitsa, Bulgaria
14 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim1,590 enrolled443 locationsNCT06632457
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 3
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Acute Ischemic Stroke
Boehringer Ingelheim1,325 enrolled224 locationsNCT07361302
Recruiting
Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
ColitisInflammatory Bowel DiseasesUlcerative Colitis
Spyre Therapeutics, Inc.645 enrolled175 locationsNCT07012395
Recruiting
Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection RecurrenceClostridium DifficileClostridioides Difficile Infection+7 more
Vedanta Biosciences, Inc.852 enrolled215 locationsNCT06237452
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Crohn's Disease
Sanofi260 enrolled138 locationsNCT06637631
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC15,000 enrolled880 locationsNCT05702034
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled291 locationsNCT06419374
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled355 locationsNCT06819878
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled331 locationsNCT06318169
Recruiting
Phase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
COVID-19
Pfizer160 enrolled73 locationsNCT05261139